J&J lures Weber Shandwick exec to Janssen; Google healthcare head joins doc-networking firm M3; Novo Nordisk taps Hispanic marketing agency;

> Google's ($GOOG) former healthcare chief signed on to head up a new European division for the physician networking business M3, which operates Doctors.net.uk and MDLinx in Europe. Release

> Novo Nordisk ($NVO) hired New York-based Prime Access to handle its diabetes marketing and advertising targeted to the U.S. Hispanic community. Release

> Weber Shandwick's SVP of global marketing and corporate affairs, Jennifer Norton, is jumping ship to join Johnson & Johnson ($JNJ) as senior director of North American communications for Janssen. Report

> Closed loop marketing software provider Agnitio launched its latest product, Rainmaker, designed to personalize marketing to individual physicians. Release

> Lundbeck and Otsuka launched their once-monthly antipsychotic drug Abilify Maintena in Europe, with Denmark first to sign up for full reimbursement. Report

> Boehringer Ingelheim's first oncology product, the lung cancer treatment Giotrif, got a preliminary thumbs-up from U.K. cost-effectiveness gatekeepers. Report

> Ashfield Meetings & Events said it won a two-year extension to its contract to provide venue services for Bayer in the U.K. Report

And Finally... AbbVie ($ABBV) is supporting two educational initiatives in Latin America, including a new master's degree through Universidad Europa de Madrid, to improve rheumatology treatment. Report

Suggested Articles

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.